[144] Centessa Pharmaceuticals plc American SEC Filing

Rhea-AI Filing Summary

A Form 144 filing from Centessa Pharmaceuticals indicates a proposed sale of 15,000 shares of common stock through UBS Financial Services. The shares have an aggregate market value of $210,000, with the sale planned for June 24, 2025 on the Nasdaq exchange.

The securities were acquired through the exercise of stock options from the issuer on June 24, 2025, with payment made in cash. The total outstanding shares of the company are 133,618,774.

Key details:

• Share price implied by filing: $14.00 per share
• No other securities sales reported by the seller in the past 3 months
• Transaction represents approximately 0.011% of total outstanding shares

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc Eleven Madison Avenue 4th Floor New York NY 10010	15000	210000.00	133618774	06/24/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/24/2025	Exercise of stock options	Issuer			15000	06/24/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares of CNTA stock are being sold according to the Form 144 filing from June 2025?

According to the Form 144 filing, 15,000 shares of CNTA common stock are being proposed for sale through UBS Financial Services, Inc., with an aggregate market value of $210,000.00.

What is the total number of outstanding shares for CNTA as reported in the June 2025 Form 144?

The Form 144 filing indicates that Centessa Pharmaceuticals plc (CNTA) has 133,618,774 shares outstanding.

How were the CNTA shares acquired by the seller according to the Form 144?

The shares were acquired through the exercise of stock options from the Issuer on June 24, 2025, with the nature of payment being cash.

What is the planned sale date for the CNTA shares reported in the Form 144?

The Form 144 indicates an approximate date of sale of June 24, 2025, with the shares to be sold on the Nasdaq exchange through UBS Financial Services, Inc.

Has the Form 144 filer sold any other CNTA shares in the past 3 months?

According to the filing section 'Securities Sold During The Past 3 Months', there is nothing to report, indicating the filer has not sold any other CNTA shares during this period.